Pan-cancer analyses on the basis of the TCGA datasets revealed that ADAR1 is also frequently amplified in several other types of cancer, including the liver hepatocellular carcinoma (LIHC), breast invasive carcinoma (BRCA), uterine carcinosarcoma (UCS) and ovarian cancer (OV) (Supplementary Fig. 2A). Here, ADAR is linked to ovarian carcinoma.